Panacea Venture Healthcare Fund II, L.P. Acquires Significant Stake in CASI Pharmaceuticals, Inc.

Panacea Venture Healthcare Fund II, L.P. has filed a Schedule 13D with the SEC, disclosing its acquisition of a significant stake in CASI Pharmaceuticals, Inc. The fund purchased 3,550,000 ordinary shares for approximately $6.7 million, representing a 19.4% ownership stake. Additionally, James Huang, a founding managing partner of Panacea Venture, has been appointed to the Board of Directors of CASI Pharmaceuticals, effective October 1, 2025. The filing indicates that the Reporting Persons acquired the securities for investment purposes and may consider various strategic actions, including potential mergers, acquisitions, or changes in management. The Reporting Persons may also engage in discussions with management, the Board, and other stakeholders to explore these opportunities. The filing does not disclose any current plans or proposals that would result in a change of control or other significant corporate actions.